Clinical Trial Enrollment in China: Detailed Explanation of Screening
Clinical Trials & Advanced Therapies
Screening is where most trial candidates are lost, and usually for reasons that were foreseeable. Understanding what the screen actually checks makes it possible to prepare documents in advance and to judge realistically whether an enrolment is likely.
The screening sequence
- Pre-screening by telephone or record review against the main criteria
- Informed consent for screening, signed before any trial-specific test
- Baseline tests: blood work, imaging, cardiac assessment, virology, pregnancy testing
- Tumour tissue confirmation, sometimes requiring a fresh biopsy
- Review by the investigator against every inclusion and exclusion criterion
- Enrolment and first dose once the window closes
Why candidates fail
- Organ function just outside the protocol range, often liver enzymes or blood counts
- Washout periods not respected for prior therapy
- Brain metastases that the protocol excludes unless treated and stable
- Prior exposure to the same drug class
- Insufficient or unassayable tumour tissue
What to prepare
- Complete treatment history with drug names, dates and best response
- Pathology report with the marker testing that the protocol requires
- Recent imaging in DICOM, not only reports
- A medication list including over-the-counter drugs and supplements
Timing and honesty
Screening windows are typically fourteen to twenty-eight days, and the window cannot be extended at will. If a criterion is marginal, ask the investigator directly rather than assuming. An early honest assessment saves a flight and, more importantly, avoids a delay in starting standard treatment that would have worked.
Next step: send your records for a pre-screening review, and we will tell you which criteria are likely to be a problem before you commit to travel.
